Login to Your Account



Pharma: Clinic Roundup


Wednesday, February 15, 2012
The ALS Therapy Development Institute (ALS TDI) said it plans to launch a Phase II trial of TDI 132 (fingolimod/Gilenya) in amyotrophic lateral sclerosis. Gilenya, a first-in-class sphingosine-1-phosphate (S1P) receptor modulator marketed by Novartis AG, of Basel, Switzerland, was approved by the FDA in 2010 to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of multiple sclerosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription